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Abstract 
Background: The optimal treatment strategy for biliary tract cancer (BTC) after curative‑intent resection remains con‑
troversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine‑based adjuvant chemotherapy 
for BTC patients undergoing microscopically margin‑negative (R0) resection.
Methods: We retrospectively analyzed the clinical data of BTC patients who underwent curative‑intent R0 resection. 
Patients were eligible if they received either fluoropyrimidine‑based adjuvant chemotherapy or observation after R0 
resection.
Results: A total of 153 patients were included. In the entire patient cohort, no significant differences were observed 
in 5‑year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3‑year recurrence‑free survival (RFS) rates (49.1% vs. 
39.5%, P = 0.299) between patients who received fluoropyrimidine‑based adjuvant chemotherapy or observation. 
However, for patients with stages II and III BTC, chemotherapy significantly improved 5‑year OS rate (52.4% vs. 35.6%, 
P = 0.002) and 3‑year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation.
Conclusion: Fluoropyrimidine‑based adjuvant chemotherapy may prolong the survival of patients with stages II and 
III BTC after R0 resection.
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Background
In western countries, biliary tract cancer (BTC) is a rare 
disease [1, 2]. However, its incidence is high in South 
Korea, where it accounts for 2.4% of all diagnosed can-
cers and is the sixth leading cause of cancer-related death 
[3]. Patients with BTC usually have a poor prognosis, and 
only 10%–35% of them have a chance to undergo cura-
tive-intent resection [4, 5]. Moreover, the recurrence rate 
is 30%–50%, even after microscopically margin-negative 
(R0) resection [6–8].
Given the high recurrence rate of BTC, adjuvant chem-
otherapy is usually administered in clinical practice. 
However, its exact role has not been determined due 
to the lack of randomized, prospective studies. Current 
information on the efficacy of adjuvant chemotherapy 
on BTC mostly comes from single-arm or retrospective 
studies. Several studies compared the efficacy of adju-
vant chemotherapy with that of surgery alone; however, 
these studies included heterogeneous patient populations 
in terms of tumor location, stage, and margin status, 
and the conflicting results made it difficult for physi-
cians to know who will benefit from adjuvant chemo-
therapy [9–15]. Some studies showed that patients with 
high-risk diseases, such as microscopically margin-pos-
itive (R1) resection disease, lymph node-positive dis-
ease, and advanced-stage disease, were likely to benefit 
from adjuvant chemotherapy [14, 15]. A meta-analysis, 
which included 20 studies with 6712 patients, showed 
that patients with BTC benefited more from adjuvant 
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chemotherapy or chemoradiotherapy than from radio-
therapy alone, and that the greatest benefit from adju-
vant therapy was observed in patients who underwent 
R1 resection and/or had lymph node-positive disease 
[4]. However, even in this meta-analysis, the efficacy of 
adjuvant chemotherapy for the patients who underwent 
R1 resection and/or had lymph node-negative disease 
remains unclear.
In this study, we aimed to evaluate the efficacy of adju-
vant chemotherapy in patients with R0-resected BTC.
Patients and methods
Patients
We reviewed the medical records of 193 consecutive 
patients who underwent surgical resection for BTC 
between March 1999 and December 2013 at Gyeong-
sang National University Hospital, Jinju, South Korea. 
BTC was defined as tumors of the gallbladder and the 
intrahepatic, perihilar, and distal bile ducts, excluding 
the ampulla of Vater. Patients were eligible for inclusion 
if they received either fluoropyrimidine-based adju-
vant chemotherapy or observation alone after resection. 
The patients who met one of the following criteria were 
excluded: (1) underwent R1 or macroscopically positive 
margin (R2) resection, (2) died of surgical complications 
within 3 months after resection, (3) treated with adjuvant 
radiotherapy or chemoradiotherapy, (4) with another pri-
mary cancer at the time of BTC diagnosis, and (5) treated 
with gemcitabine-based adjuvant chemotherapy. This 
study was approved by the Institutional Review Board of 
Gyeongsang National University Hospital.
Treatment
Curative-intent R0 resection was performed in all 
patients in the present study, and the subsequent adjuvant 
chemotherapy plan and schedule were decided according 
to the clinicians’ discretion. Adjuvant chemotherapy was 
started within 6–8  weeks after surgery. Patients in the 
adjuvant chemotherapy group were treated with either 
single fluoropyrimidine-based chemotherapy—includ-
ing intravenous 5-fluorouracil (5-FU) and oral agents 
such as doxifluridine, uracil, and tegafur (UFT); capecit-
abine; and S-1—or combination chemotherapy consist-
ing of 5-FU and cisplatin. Intravenous chemotherapy 
consisted of 5-FU (450  mg/m2  per  day) and leucovorin 
(20 mg/m2 per day) for 5 days every 4 weeks for 6 cycles, 
or 5-FU (1000 mg/m2 on days 1–4) and cisplatin (60 mg/
m2 on day 1) every 3 weeks for 8 cycles. Oral regimens 
were as follows: doxifluridine, 800 mg/day in two divided 
doses for 1  year; capecitabine, 1250  mg/m2 twice daily 
on days 1–14 every 3 weeks for 8 cycles; S-1, 40–60 mg 
twice daily according to body surface area on days 1–14 
every 3 weeks for 8 cycles; or UFT, 300 mg/m2 per day in 
three divided doses for 1 year. Patients in the observation 
group were followed up after surgery without adjuvant 
chemotherapy or radiotherapy. Regular assessments were 
performed in each group using comprehensive physi-
cal examinations, tumor marker analysis, and computed 
tomography to detect recurrence in each group.
Clinical data collection
By medical chart review, data on the patient characteris-
tics, including demographics, tumor location, histology, 
TNM stage based on the American Joint Committee on 
Cancer (AJCC) Cancer Staging Manual (7th edition), 
lymph nodal status, preoperative serum carbohydrate 
antigen 19-9 (CA 19-9) level, and chemotherapeutic 
agents, were collected. The cut-off value of serum CA 19-9 
level was defined as 37 U/mL (the upper limit of normal 
range). Survival and recurrence data were also obtained 
from the medical records. Overall survival (OS) was 
defined as the time from the date of surgery to the date 
of death or the last follow-up visit. Recurrence-free sur-
vival (RFS) was defined as the time from the date of sur-
gery to the date of first recurrence at any site or death. The 
follow-up consisted of abdominal computed tomography 
every 6 months during the first 3 years and yearly there-
after. If signs or symptoms indicated a possible recur-
rence, investigations were then done to verify whether the 
patient was recurrence-free. The follow-up cut-off date 
was January 21, 2014. Recurrences were divided into three 
patterns: locoregional recurrence, distant metastasis only, 
and both locoregional and distant recurrence. Locore-
gional and distant recurrences were defined as recurrent 
disease within and outside 20 mm of the resection margin 
or regional lymph node, respectively.
Statistical analysis
Categorical variables are presented as frequencies and 
percentages, and continuous variables are expressed as 
means  ±  standard deviations. Clinical data were com-
pared using the Chi squared test or Fisher’s exact test for 
categorical variables and the Mann–Whitney U test for 
continuous variables. OS and RFS were estimated using 
the Kaplan–Meier method and were compared using the 
log-rank test between two groups. All significant vari-
ables in univariate analysis were included in multivariate 
analysis. Multivariate analysis using the Cox proportional 
hazards model with entering selection method was per-
formed to adjust for potential confounding factors. The 
results are presented as hazard ratios (HRs) and 95% con-
fidence intervals (CIs). A two-tailed P value <0.05 was 
considered statistically significant. Missing data were 
omitted, and the remaining data were analyzed. SPSS 
software for Windows, version 21.0 (SPSS Inc., Chicago, 
IL, USA) was used for all statistical analyses.
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Results
Patient characteristics
A total of 153 patients were included in the study; of 
them, 89 (58.2%) received fluoropyrimidine-based adju-
vant chemotherapy, and 64 (41.8%) were observed after 
surgery. Forty patients were excluded for the following 
reasons: R1 or R2 resection (n = 23); early death due to 
surgical complication (n  =  7); treatment with adjuvant 
radiotherapy or chemoradiotherapy (n  =  4); another 
primary cancer (n  =  4); and gemcitabine-based adju-
vant chemotherapy (n  =  2). Characteristics of patients 
in the adjuvant chemotherapy and observation groups 
are shown in Table 1. Although there were more men in 
the observation group, no significant differences were 
observed in age, tumor location, histologic grade, TNM 
stage, lymph node status, or preoperative serum level 
of CA 19-9 between two groups. Most tumors were 
located in the gallbladder (77/153, 50.3%) and intrahe-
patic bile duct (51/153, 33.3%). In the adjuvant chemo-
therapy group, doxifluridine was most commonly used 
(74/89, 83.1%), followed by 5-FU with leucovorin (6/89, 
6.7%), 5-FU with cisplatin (4/89, 4.5%), S-1 (3/89, 3.4%), 
capecitabine (1/89, 1.1%), and UFT (1/89, 1.1%). Sixty-
three of the 153 (41.2%) patients experienced a recur-
rence. The patterns of recurrence and the proportions of 
patients who received additional cancer treatment after 
recurrence were not significantly different between two 
groups (Table 2).
Survival analysis
With a median follow-up of 61.2  months (range 1.1–
178.2  months), 46 patients in the adjuvant chemother-
apy group and 20 patients in the observation group died 
of disease-related causes. In the entire patient cohort, 
5-year OS rates (48.4% vs. 39.6%, P = 0.439) and 3-year 
RFS rates (49.1% vs. 39.5%, P = 0.299) did not differ sig-
nificantly between the two groups.
To assess the relationship between tumor burden and 
the efficacy of fluoropyrimidine-based adjuvant chemo-
therapy, we compared the outcomes of patients with 
various primary TNM stage diseases between the adju-
vant chemotherapy and observation groups. In patients 
with stages I and IV disease, the adjuvant chemotherapy 
group did not show significant differences in 5-year OS 
rate compared with the observation group (P = 0.612 and 
P = 0.161, respectively); whereas in patients with stages II 
and III diseases, the adjuvant chemotherapy group had a 
higher 5-year OS rate than the observation group (52.4% 
vs. 35.6%, P = 0.002; Fig. 1a). The benefit of chemother-
apy was similar in terms of RFS. In patients with stages I 
and IV diseases, no significant difference in 3-year RFS 
rate was observed between the adjuvant chemother-
apy and observation groups (P =  0.785 and P =  0.116, 
respectively). However, in patients with stages II and III 
disease, the adjuvant chemotherapy group showed higher 
3-year RFS rate than the observation group (55.5% vs. 
39.1%, P = 0.021; Fig. 1b).
Additionally, we analyzed the association between 
the efficacy of adjuvant chemotherapy and other clini-
cal variables (Table  3). The effects of adjuvant chemo-
therapy appeared to differ depending on tumor locations. 
In patients with distal bile duct cancer, adjuvant chemo-
therapy was associated with prolonged OS (P  =  0.014) 
and RFS (P  =  0.016) compared with observation. In 
patients with gallbladder cancer, adjuvant chemotherapy 
tended to improve OS rate (P = 0.057), but not RFS rate 
(P  =  0.148). On the other hand, no significant survival 
benefit from adjuvant chemotherapy was observed in 
patients with intrahepatic cholangiocarcinoma or peri-
hilar cholangiocarcinoma. When patients were stratified 
by other clinical variables such as age, lymph node sta-
tus, preoperative serum CA 19-9 level, and histology, no 
significant differences in OS and RFS rates were observed 
between the adjuvant chemotherapy and observation 
groups.
Multivariate analysis for survival
For 85 patients with stages II and III diseases, lymph 
node-negative disease, low serum CA 19-9 level, and 
fluoropyrimidine-based adjuvant chemotherapy were 
favorable predictors for OS and RFS in univariate anal-
ysis. In multivariate analysis, low serum CA 19-9 level 
and fluoropyrimidine-based adjuvant chemotherapy 
were independent favorable predictors for OS and RFS 
(Table 4).
Discussion
Positive resection margin is considered an important pre-
dictor of poor prognosis in BTC patients who undergo 
surgery [2, 16–18]. Previous studies reported that adju-
vant therapy was beneficial to BTC patients with R1 or R2 
resection [4, 9, 15, 19]. Takada et al. [9] reported that the 
5-year survival rate in patients with stages II–IV gallblad-
der cancer was significantly higher in the adjuvant chem-
otherapy group treated with mitomycin C and 5-FU than 
in the surgery alone group. In the subgroup analysis, the 
benefit of adjuvant chemotherapy to gallbladder cancer 
was observed only in patients with non-curative resec-
tion, not in those with R0 resection [9]. Another recent 
study showed the benefits of adjuvant chemotherapy in 
high-risk BTC patients with high CA 19-9 level, advanced 
disease, lymph node involvement, and R1 resection, but 
not in those with R0 resection [15]. Moreover, the two 
studies did not stratify patients with R0 resection by spe-
cific prognostic factors; thus, it was difficult to conclude 
who would benefit from adjuvant chemotherapy. In our 
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Table 1 Comparison of characteristics between two groups of biliary tract cancer (BTC) patients undergoing microscopi-
cally margin-negative (R0) resection
AJCC American Joint Committee on Cancer (7th edition), CA 19-9 carbohydrate antigen 19-9
a Except these, other values are presented as number of patients with percentage in parentheses
b Includes undifferentiated carcinoma (n = 3), signet ring cell carcinoma (n = 2), carcinosarcoma (n = 2), pleomorphic carcinoma (n = 1), and large cell 
neuroendocrine carcinoma (n = 1)
c All patients had intrahepatic bile duct cancers; 12 patients had TxN1M0 disease and 1 had T4N0M0 disease
d Baseline CA 19-9 levels were available for 77 patients in the adjuvant chemotherapy group and 49 patients in the observation group
Characteristic Adjuvant chemotherapy (n = 89) Observation (n = 64) P value
Age (years)a 0.072
Median (range) 64 (36–83) 67 (47–80)
Gender 0.048
Male 50 (56.2) 46 (71.9)
Female 39 (43.8) 18 (28.1)
Tumor location 0.480
Gallbladder 43 (48.3) 34 (53.1)
Intrahepatic bile duct 33 (37.1) 18 (28.1)
Perihilar bile duct 3 (3.4) 5 (7.8)
Distal bile duct 10 (11.2) 7 (10.9)
Histologic differentiation 0.225
Well 34 (38.2) 25 (39.1)
Moderate 31 (34.8) 30 (46.9)
Poor 17 (19.1) 7 (10.9)
Unspecifiedb 7 (7.9) 2 (3.1)
AJCC stage 0.152
I 26 (29.2) 29 (45.3)
II 35 (39.3) 20 (31.2)
III 18 (20.2) 12 (18.8)
IVAc 10 (11.2) 3 (4.7)
Lymph node involvement 0.426
Yes 23 (25.8) 13 (20.3)
No 66 (74.2) 51 (79.7)
CA 19‑9 (U/mL) (n = 126)a, d 0.328
Median (range) 25.3 (0.1–11,150.0) 17.6 (0.6–9700.0)
Table 2 Comparison of patterns of recurrence and post-recurrence therapies between two groups of BTC patients under-
going R0 resection
All values are presented as number of patients with percentage in parentheses
a Three patients in the adjuvant chemotherapy group and two in the observation group received surgery and chemotherapy after recurrence
b This patient underwent concurrent chemoradiotherapy after recurrence
Item Adjuvant chemotherapy (n = 41) Observation (n = 22) P value
Pattern of recurrence 0.893
Locoregional 9 (22.0) 5 (22.7)
Distant 21 (51.2) 10 (45.5)
Both 11 (26.8) 7 (31.8)
Post‑recurrence therapy
Patients with any post‑recurrence therapya 23 (56.1) 9 (40.9) 0.250
Chemotherapy 18 (43.9) 7 (31.8) 0.350
Surgery 3 (7.3) 2 (9.1) 1.000
Radiotherapy 4 (7.3) 1 (4.5)b 0.650
Unknown 1 (2.4) 1 (4.5) 1.000
Page 5 of 9Kim et al. Chin J Cancer  (2017) 36:9 
study, we investigated the efficacy of fluoropyrimidine-
based adjuvant chemotherapy in BTC patients with R0 
resection. When the cohort was analyzed without strati-
fication, no improved survivals were observed in the 
adjuvant chemotherapy group. However, after stratifi-
cation, in patients with stages II and III disease, OS and 
RFS were extended by fluoropyrimidine-based adjuvant 
chemotherapy compared with observation alone. The 
efficacy of fluoropyrimidine-based adjuvant chemother-
apy in patients with stages II and III BTC who underwent 
R0 resection was confirmed by multivariate analysis. 
Similarly, Yamanaka et  al. [14] included only patients 
who underwent R0 resection for BTC and showed that 
adjuvant gemcitabine chemotherapy for BTC may be 
effective, particularly for patients with stage III BTC or 
intrahepatic bile duct cancer. Controversies of adjuvant 
chemotherapy for R0-resected BTC suggest that patients 
with other risk factors, such as poor tumor differentia-
tion, lymphovascular invasion, perineural invasion, and 
lymph node involvement, need to be considered candi-
dates for adjuvant chemotherapy after R0 resection.
Different from previous studies which showed that 
adjuvant therapy was associated with prolonged sur-
vival in patients with lymph node involvement [4, 15, 
20, 21], our study showed that lymph node involvement 
did not identify patients who benefited from fluoropy-
rimidine-based adjuvant chemotherapy after R0 resec-
tion. Lymph node involvement indicates stages IIIB to 
IV BTC according to the AJCC Cancer Staging Manual 
(7th edition), with the exception of distal bile duct cancer. 
Since patients with stage IV disease in our study did not 
benefit from fluoropyrimidine-based adjuvant chemo-
therapy, lymph node involvement might not be a strati-
fication factor to identify those who will benefit from 
fluoropyrimidine-based adjuvant chemotherapy. There 
are several possible reasons why no survival benefit from 
adjuvant chemotherapy was observed in patients with 
stage IV disease. First, the number of patients with stage 
IV disease (n = 13) was too small to have a significant dif-
ference in survival. Second, the chemotherapies in our 
study were limited to fluoropyrimidine-based regimens. 
Given that combination chemotherapy of gemcitabine 
and cisplatin is considered standard care for patients 
with advanced BTC [22], fluoropyrimidine-based adju-
vant chemotherapy might not be the optimal treatment 
of patients with stage IV disease, even after R0 resec-
tion. Several studies evaluated gemcitabine-based adju-
vant chemotherapy. Two Japanese studies showed that, 
as adjuvant chemotherapy, gemcitabine alone [14] or in 
combination with S-1 [11] prolonged OS compared with 
observation in the control group in patients with BTC. 
Neoptolemos et  al. [13] found no difference in survival 
between adjuvant gemcitabine and fluorouracil plus leu-
covorin in patients with BTC. However, unlike our study, 
these studies of gemcitabine-based adjuvant chemother-
apy included patients with ampulla of Vater cancer [11, 
13, 14], which might have different biologic characteris-
tics compared with BTC [23] or with R1-resected BTC 
[11, 13]. Comparisons between previous studies and our 
study are shown in Table  5. Further studies are needed 
to determine which regimen of adjuvant chemotherapy is 
more effective for BTC patients with R0 resection.
Biliary tract cancer is a heterogeneous disease that is 
anatomically subdivided. Resectability and surgical man-
agement vary depending on the tumor location. Each 
subtype is considered to have different tumor biology 
and prognosis [24]. In BTC patients receiving adjuvant 
therapy, it is also debatable which location of primary 
Fig. 1 Kaplan–Meier survival curves of patients with stages II and III biliary tract cancer after microscopically margin‑negative resection in the 
fluoropyrimidine‑based adjuvant chemotherapy and observation groups. a Overall survival. b Recurrence‑free survival
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tumor is associated with improved survival. Jarnagin et al. 
[6] suggested that, based on the pattern of initial recur-
rence, locoregional adjuvant therapy is unlikely to have a 
significant effect on gallbladder cancer, whereas evidence 
supports its use in perihilar bile duct cancer. However, 
other studies showed that adjuvant chemoradiotherapy 
improved survival in patients with lymph node-positive 
gallbladder cancer [20, 21] or distal bile duct cancer [25, 
26], but not in those with intrahepatic or perihilar bile duct 
cancer [25]. With respect to chemotherapy, as described 
above, benefits from adjuvant therapy were seen only in 
patients with gallbladder cancer [9] or intrahepatic bile 
duct cancer [14]. By contrast, a meta-analysis showed that 
there was no difference in survival between patients with 
gallbladder and bile duct cancers (P  =  0.68) [4]. In our 
study, in patients with stages II and III distal bile duct can-
cer, fluoropyrimidine-based adjuvant chemotherapy was 
associated with significant improvement in both OS and 
RFS. However, this result should be interpreted with cau-
tion, considering the small number of patients (n =  17). 
Currently, it is difficult to determine which treatment—
adjuvant chemotherapy or chemoradiotherapy—is more 
effective on the primary tumor sites in patients with BTC, 
especially in those undergoing R0 resection.
Table 3 Subgroup analysis of survival between two groups of BTC patients undergoing R0 resection
OS overall survival, RFS recurrence-free survival, CA 19-9 carbohydrate antigen 19-9, W/D well-differentiated, M/D moderately differentiated, P/D poorly differentiated
a Baseline CA 19-9 levels were unavailable for 12 patients in the adjuvant chemotherapy group and 15 patients in the observation group
b Seven patients in the adjuvant chemotherapy group and 2 patients in the observation group had unspecified carcinoma
Variable 5-year OS rate (%) P value 3-year RFS rate (%) P value
Adjuvant chemotherapy Observation Adjuvant chemotherapy Observation
Tumor location
Gall bladder 62.5 52.3 0.057 69.7 58.1 0.148
Bile duct 35.2 26.9 0.577 30.8 12.5 0.720
Intrahepatic bile duct 27.5 0 0.265 22.8 32.5 0.549
Distal bile duct 72.9 50.0 0.014 70.0 25.0 0.016
Perihilar bile duct 0 66.7 0.139 0 33.3 0.066
Age (years)
<65 50.3 62.1 0.723 49.4 25.3 0.479
≥65 45.8 25.2 0.570 48.6 41.2 0.508
Lymph node involvement
Yes 23.0 23.8 0.121 21.7 15.6 0.222
No 57.9 39.6 0.587 59.3 44.2 0.336
CA 19‑9 level (U/mL)a
<37 58.7 75.6 0.195 62.1 76.7 0.430
≥37 34.8 27.9 0.196 32.3 0 0.158
Histologic differentiationb
W/D 71.3 73.5 0.741 68.9 60.3 0.519
M/D or P/D 36.6 29.0 0.476 39.7 24.9 0.325
Table 4 Multivariate analysis of survival in patients with stages II and III BTC
CI confidence interval, CA 19-9 carbohydrate antigen 19-9
Prognostic factor Hazard ratio 95% CI P value
Overall survival
Lymph node (negative vs. positive) 0.461 0.208–1.021 0.056
Serum CA 19‑9 level (<37 vs. ≥37 U/mL) 0.379 0.177–0.811 0.012
Treatment (adjuvant chemotherapy vs. observation) 0.231 0.087–0.617 0.003
Recurrence‑free survival
Lymph node (negative vs. positive) 0.579 0.269–1.250 0.164
Serum CA 19‑9 level (<37 vs. ≥37 U/mL) 0.392 0.189–0.811 0.012
Treatment (adjuvant chemotherapy vs. observation) 0.385 0.161–0.923 0.032













































































































































































































































































































































































































































































































































































Page 8 of 9Kim et al. Chin J Cancer  (2017) 36:9 
The present study had several limitations. First, this 
analysis was based on retrospective data from a sin-
gle institution; thus, biases to single institution could 
not be completely avoided. Second, adjuvant chemo-
therapy consisted of several different chemotherapeutic 
regimens. Finally, the small sample size of patients with 
tumors in each anatomical location was insufficient to 
generalize our findings. Therefore, a randomized con-
trolled trial comprising a large number of homogeneous 
patients with BTC is needed to confirm the efficacy of 
adjuvant treatment.
In conclusion, we found that fluoropyrimidine-based 
adjuvant chemotherapy improved survival in patients 
with stages II and III BTC after R0 resection. Patients 
with stage I disease may not benefit from adjuvant chem-
otherapy, and other therapeutic strategies may be con-
sidered in those with stage IV disease. In addition, the 
effect of adjuvant therapy appears to differ depending on 
the primary tumor site. Further large prospective studies 
are needed to validate our findings and to compare fluo-
ropyrimidine-based adjuvant chemotherapy with other 
therapeutic options, such as gemcitabine-based chemo-
therapy and chemoradiotherapy, in BTC patients with R0 
resection.
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